Primary endpoint:target lesion failurefor BP-SES vs. DP-SES:6.3% vs. 6.1%,pnoninferiority=0.0002Cardiac death: 0.7% vs. 0.6%,p = 0.62;target vesselMI: 3.6% vs. 4.3%,p = 0.39; TLR: 2.6% vs. 2.2%,p = 0.5; definite/probablestentthrombosis: 0.4% vs. 0.6%,p = 0.55
Trial design:Chinese patients with CAD undergoing PCI were randomized ina 2:1 fashion to receiveeither biodegradable(PLGA) polymer-coatedSES (BP-SES) ordurable polymer-coated SES(DP-SES). Patientswere followed for1 year.
Han Y, et al. JACCCardiovascInterv2014;Sep 16:[Epub]
Primary endpoint at 1 year
BP-SESisnoninferiorto DP-SES for clinical outcomes including stent thrombosis at 1 year in patients undergoingPCIDP-SES is not the sameasCypher® SES, which was on a stainless steelplatform; thistrial adds to the literature onbioresorbablestentsLonger-term follow-up data are awaited